SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation D565H

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 A Multi Center, Randomized, Double-blind, Parallel Design, Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily in Primary Open Angle Glaucoma or Ocular Hypertension Patients.

Exploratory trial to evaluate the efficacy and safety of D565H twice daily versus D565 once daily.

NCT03067415 Glaucoma, Primary Open Angle Ocular Hypertension Drug: D565H(Latanoprost 25㎍/㎖) Drug: D565(Latanoprost 50㎍/㎖)
MeSH:Glaucoma Ocular Hypertension Glaucoma, Open-Angle Hypertension
HPO:Glaucoma Hypertension

A Multi Center, Randomized, Double-blind, Parallel Design, Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily in Primary Open Angle Glaucoma or Ocular Hypertension Patients.. Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily Exploratory trial to evaluate the efficacy and safety of D565H twice daily versus D565 once daily. --- D565H ---

A Multi Center, Randomized, Double-blind, Parallel Design, Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily in Primary Open Angle Glaucoma or Ocular Hypertension Patients.. Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily Exploratory trial to evaluate the efficacy and safety of D565H twice daily versus D565 once daily. --- D565H --- --- D565H ---

A Multi Center, Randomized, Double-blind, Parallel Design, Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily in Primary Open Angle Glaucoma or Ocular Hypertension Patients.. Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily Exploratory trial to evaluate the efficacy and safety of D565H twice daily versus D565 once daily. --- D565H --- --- D565H --- --- D565H ---

Impossible subjects who participate in clinical trial by investigator's decision Glaucoma, Primary Open Angle Ocular Hypertension Glaucoma Ocular Hypertension Glaucoma, Open-Angle Hypertension A Multi center, Randomized, Double-blind, Parallel design, Exploratory trial to evaluate the efficacy and safety of D565H twice daily versus D565 once daily in primary open angle glaucoma or ocular hypertension patients. --- D565H ---

Primary Outcomes

Description: Mean baseline intraocular pressure change Mean intraocular pressure change after 4 weeks

Measure: Change in mean intraocular pressure at 4 weeks compared to baseline

Time: Baseline, 4 weeks

Secondary Outcomes

Description: Mean baseline intraocular pressure change Mean intraocular pressure change after 2 weeks

Measure: Change in mean intraocular pressure at 2 weeks compared to baseline

Time: Baseline, 2 weeks

Description: IOP variation by measurement time

Measure: Changes in intraocular pressure by measurement time

Time: 2 weeks, 4 weeks

Other Outcomes

Description: Adverse events, history, medications, signs of vitality, physical examination, etc.

Measure: Safety assessed by the incidence of adverse event, History, Medication

Time: up to 4 weeks


HPO Nodes


HP:0000501: Glaucoma
Genes 386
COL2A1 HGSNAT RP1 PEX13 NAA10 TRAIP POMT2 COL1A1 TRIM44 PEX1 PEX6 TTC37 POMGNT1 MAK IFT172 BEST1 FSCN2 CRX SETD5 BUB1 BBS2 CRB1 CHRDL1 LARGE1 OCRL PEX12 MAFA IDUA DAG1 RP9 DSE WT1 RECQL4 WFS1 NTF4 PTCH2 GLIS3 ACVR1 LTBP2 COL11A1 CHST14 HDAC8 PEX2 TBX1 PEX11B LTBP2 PRPF4 CRYAA TUB VCAN ZSWIM6 POMK RHO LOXL1 KMT2A RBBP8 AKT1 CYP1B1 FKRP OPTN WDR36 SAG PITX2 USH2A UFD1 PRPF6 PITX2 LRP5 RNASEH2A CNGA1 B3GLCT MERTK LTBP2 PXDN YAP1 TEK ARHGEF18 IDH3B DDX58 PRPF3 SLC7A14 NDP MYOC VHL NDUFB11 NDP JMJD1C ANTXR1 CBS EBP FAT4 MYOC COX7B WT1 FOXC1 FUT8 PTPN22 NCAPG2 CCBE1 HLA-DRB1 FAS PTEN ARSB TWIST1 ATR PEX19 SCAPER PRCD SEC24C SMC1A PCARE B3GLCT NF1 FREM2 LTBP2 POMT1 DHDDS AGK ADAMTS3 GJA1 ZNF513 FBN1 OCRL TEK ZNF469 GUCA1B POMGNT1 YARS2 COL5A2 IDUA POMT1 FOXE3 CHST3 PLOD1 PAX6 SUFU COMT FBN1 GJA1 PITX2 ROM1 C8ORF37 ANKLE2 POMT1 PDE6B CCDC22 BEST1 AGK PEX5 PDE6G LARGE1 NOD2 MAG RXYLT1 PITX2 RGR PAX6 PEX3 TREX1 PROM1 SEMA4A PEX10 FKRP ARL6 CANT1 NHS ASB10 ABCA4 ELN TULP1 TGFB1 CBS REEP6 B3GALNT2 RREB1 BUB3 SRY LMX1B PTCH1 FKTN DHX38 MASP1 BCOR POMT2 GJB4 XYLT1 HLA-DRB1 COL2A1 RP2 RLBP1 WASHC5 GP1BB PUS1 CEP57 RFC2 POMT2 FOXE3 PEX1 FOXC1 WFS1 EP300 ADAMTS10 FGFR2 IFIH1 FKTN STUB1 ARL3 IFT88 OFD1 PAX6 CYP1B1 B3GAT3 PIK3R1 RDH12 SUFU SLC4A4 BEST1 IDUA SMC3 IDH3A PEX26 POMGNT1 PITX2 FKTN CISD2 MAB21L1 CYP1B1 B4GAT1 TBC1D20 FBN1 LIMK1 TBL2 RNASEH2B ARL2BP IMPG2 BDNF RBP3 KIZ PRPF8 TOPORS TMEM98 GJB3 GMPPB RPGR FKTN ESCO2 ADAMTSL1 GSN KIF11 EXOSC2 FAM161A PEX14 CYP1B1 WFS1 CRPPA IFIH1 PTCH2 CYP1B1 HIRA PIK3C2A CCBE1 SIX6 RAD21 BBS1 TIMP3 COL2A1 NOD2 POMGNT1 CLIP2 LARGE1 DAG1 ANTXR1 NIPBL NR2E3 PYCR1 KIAA1549 KLHL7 ADAMTS10 BUB1B CNGB1 COL4A1 PRSS56 ADAR AGBL5 COL11A1 DHCR7 FBN1 CA4 KDSR NLRP3 SH3PXD2B ADAMTS17 PLK4 IDUA EYS LMX1B NEK2 COL4A1 NHS CERKL FLNA RRM2B BCOR RASA1 BCOR SKIV2L FOXC1 CLN3 COL3A1 CHST14 GNAQ PRDM5 CCDC28B PIK3R1 ZSWIM6 ZNF408 TRIP13 CRYBA2 CANT1 FKRP CDHR1 PRPF31 TRIM44 TEK PCNT PAX6 GJA1 ARVCF GTF2I CRPPA MYMK LRAT RS1 OVOL2 PRPH2 RNASEH2C COL5A1 MYOC BTNL2 CLRN1 GNAQ NRL PDE6A RNU4ATAC RPS19 TBX1 HCCS CENPJ GZF1 FBN1 CRB1 TTC8 SAMHD1 ATOH7 CENPE RPE65 CEP152 DCN AHI1 SPATA7 BAZ1B SNRNP200 CDH11 CYP1B1 AHR COL11A1 PEX16 POMGNT2 LTBP2 ATRIP PAX6 POMT2 SLC25A4 PLOD1 IMPDH1 IFT140 B3GALNT2 FOXC1 SBF2 FOXC1 MFRP GTF2IRD1 GNAQ PTCH1 CREBBP CRYBB3
HP:0000822: Hypertension
Genes 418
PDE11A WT1 BBS10 TGFB2 COL1A1 KCTD1 MLX ND5 SCNN1A GPR101 TRNS2 B2M CFI NOTCH3 ALX4 TNFRSF11A GATA5 EXT2 LYZ MUC1 ERCC6 TRNL1 STOX1 COX3 PRKACA MTTP BSCL2 TRNS1 PKD2 KRT8 TRNL1 SLC2A10 CDH23 LEMD3 WT1 TBX1 TRIM28 KCTD1 ND1 CYTB WNK1 ELP1 WDR19 AIP COX2 LOX TGFBR2 GCH1 KRT18 SCNN1B CORIN UFD1 CFH SCNN1G HGD PDE11A COL4A4 BRCA2 NR3C1 CACNA1D LMNA FBN1 ND1 TRNQ VHL JMJD1C CBS RPGRIP1L TGFBR3 POR SDHD TRNS1 ALMS1 CACNA1H TSC1 LRP6 CD2AP FBN1 COX2 DYRK1B SEC24C ADA2 HPSE2 NF1 LDLRAP1 HLA-DRB1 WNK4 ACVRL1 CCND1 FBN1 VHL GLA PDE3A ABCG8 SH2B3 MMP2 SLC52A2 ARMC5 SLC25A11 ERCC4 BBIP1 PAM16 HLA-DPA1 PDE8B ACAT1 LMNA GLA GUCY1A1 MAFB DIS3L2 COL5A2 NKX2-5 CYP11B1 TRNL1 BBS1 FGFR2 LEMD3 MYH7 PPARG FLT1 FN1 COMT MYMK MTRR FOXF1 FN1 CFB MKKS SDHD CYP11B1 MGP SDCCAG8 GJA1 SH2B3 CYP17A1 SUGCT TGFB3 COX1 ANGPTL6 ELN ACTN4 REST HMBS HSD11B2 ND5 SDHD SMAD4 ND4 KCNJ5 LRIG2 NPHP1 TRNQ FMO3 HMBS PTPN22 FGFR2 GBA ELN KIF1B SDHB SLC2A10 COX1 ENG RREB1 CCR6 CYP11B1 PLIN1 CCN2 LMX1B ACTA2 CD46 VHL CACNA1D G6PC PPARG MMP14 NPHP1 WRN APOA1 GP1BB KCNJ5 GPC3 ARHGAP31 RFC2 SMAD3 ND6 MAX SCNN1B ND6 CTLA4 PRTN3 SCNN1G RET PLIN1 USP8 C3 XYLT1 HLA-B XYLT2 FGA TRNC TRNF EPAS1 APOB BBS7 BBS2 BNC2 FOXE3 SDHC IQCB1 NOS3 BBS9 ABCC6 KIF1B COL4A5 H19 EDA2R CYP17A1 ELN PKHD1 HBB ENPP1 LIMK1 TBL2 LZTFL1 CPOX CEP164 USP8 CALR KIF1B SLC37A4 ZMPSTE24 TRNF SERPINA6 TMEM67 VHL JAK2 MDH2 ARMC5 SMARCAL1 FUZ ABCC6 TRNW POU3F4 SDHB NSMCE2 OFD1 MEF2A WT1 KLHL3 XPNPEP3 HIRA GNAS TP53 PDE3A CEP19 BANF1 SPRY2 INVS ADA2 BBS1 FBN1 NOD2 SDHC CLIP2 ERCC8 HSD11B2 NPHP3 TMEM127 HLA-DPB1 TNFRSF11B SDCCAG8 DLST MC4R CEP290 EGFR STAT1 TMEM127 COL3A1 YY1AP1 CAV1 COQ7 INVS ADA2 NOTCH1 TRNK BBS12 NFIX TRIP13 TRPC6 IDUA OFD1 LMX1B WDR35 ENPP1 BMPR2 CEP290 MFAP5 LMNA TRNK MKS1 POU6F2 PKD1 CC2D2A MAT2A MYH11 LDLR RET COL3A1 VHL CCDC28B SCN2B SDHB NOTCH2 ECE1 CDH23 IFT27 TRNV SMAD4 TRIM32 SDHAF2 GNAS MYLK ALMS1 ARL6 TSC2 AIP PRKAR1A WT1 ITGA8 TRIM28 ARVCF GTF2I LARS2 TRNW THPO COX3 CYP11B2 TMEM237 SLC37A4 CYP11B1 IFT172 COL5A1 SMAD6 TRAF3IP1 TMEM70 TRNH FH DNAJB11 NFU1 CFHR1 TBX1 BBS4 KCNJ5 COL4A3 AIP TRNS2 NR3C1 MLXIPL NPHP1 LMNA GUCY1A1 EDA SLC25A11 ACTA2 SCNN1A CFHR3 FMR1 LMNA TTC8 PRKG1 PRKACA TGFBR1 FIG4 ELP1 BAZ1B IL12B MAX IRF5 NPHP4 PHF21A ABCC6 RET WDPCP YY1AP1 CUL3 COL4A3 ADAMTSL4 BBS5 SLC52A3 OSGEP GANAB GNAS CYP21A2 TRNE SDHB ABCB6 VAC14 JAK2 RET SDHA PRKAR1A SDHD PCSK9 GDNF WT1 TET2 NR3C2 SMAD4 CLCN2 ABCG5 MPL C8ORF37 GTF2IRD1 VANGL1 TRNK THBD PRKAR1A